Jaguar Health

Napo Therapeutics, a Jaguar Health company, named 'Best Pharmaceuticals Innovator of the Year - Europe' for advancing crofelemer, an oral plant-based drug for rare diseases like MVID and SBS, with Phase 2 trials planned for 2024.

Jaguar Health reported Q3 2024 revenue of $3.1M, up 14% QoQ and 11% YoY, with a net loss of $9.9M. Key milestones include Phase III OnTarget trial results, crofelemer advancement in rare diseases, and Gelclair launch for oral mucositis. The company anticipates significant catalysts in the next six months, focusing on unmet patient needs and financial stability.

Jaguar Health's cofelemer delayed-release tablets (Canalevia-CA1) received FDA renewal for treating chemotherapy-induced diarrhea (CID) in dogs, with active progress toward full approval.

Jaguar Health, Inc. received FDA renewal for conditional approval of Canalevia-CA1, a canine-specific drug for chemotherapy-induced diarrhea (CID) in dogs, until December 2025. The company is pursuing full FDA approval through a clinical field study. Canalevia-CA1 is the only FDA conditionally approved oral plant-based prescription treatment for CID in dogs, derived from the Croton lechleri tree.

Jaguar Health announces FDA renewal of Canalevia-CA1, the only approved treatment for chemotherapy-induced diarrhea in dogs, extending conditional approval until December 2025.

Change effective immediately; card charged prorated amount based on subscription level. Options: OK or Cancel.

Jaguar Health's Napo Pharmaceuticals launches FDA-approved Gelclair for oral mucositis in the U.S., aiming to provide pain relief without stinging or drying effects. Oral mucositis, a common side effect in cancer patients, particularly head and neck cancer, affects up to 90% of such patients undergoing chemotherapy and radiotherapy.